Comparison of NITAG policies and working processes in selected developed countries.

Abstract:

BACKGROUND:Vaccines are specific medicines characterized by two country-specific market access processes: (1) a recommendation by National Immunization Technical Advisory Group (NITAG), and (2) a funding policy decision. OBJECTIVES:The objective of this study was to compare and analyze NITAGs of 13 developed countries by describing vaccination committees' bodies and working processes. METHODS:Information about NITAGs bodies and working processes was searched from official sources from June 2011 to November 2012. Retrieved information was completed from relevant articles identified through a systematic literature review and by information provided by direct contact with NITAGs or parent organizations. An expert panel was also conducted to discuss, validate, and provide additional input on obtained results. RESULTS:While complete information, defined as 100%, was retrieved only for the UK, at least 80% of data was retrieved for 9 countries out of the 13 selected countries. Terms of references were identified in 7 countries, and the main mission for all NITAGs was to provide advice for National immunization programs. However, these terms of references did not fully encompass all the actual missions of the NITAGs. Decision analysis frameworks were identified for 10 out of the 13, and all NITAGs considered at least four criteria for decision-making: disease burden, efficacy/effectiveness, safety and cost-effectiveness. Advices were published by most NITAGs, but few NITAGs published meeting agendas and minutes. Only the United States had open meetings. CONCLUSIONS:This study supports previous findings about the disparities in NITAGs processes which could potentially explain the disparity in access to vaccinations and immunization programs across Europe. With NITAGs recommendations being used by policy decision makers for implementation and funding of vaccine programs, guidances should be well-informed and transparent to ensure National Immunization Programs' (NIP) credibility among the public and health care professionals.

journal_name

Vaccine

journal_title

Vaccine

authors

Ricciardi GW,Toumi M,Weil-Olivier C,Ruitenberg EJ,Dankó D,Duru G,Picazo J,Zöllner Y,Poland G,Drummond M

doi

10.1016/j.vaccine.2014.09.023

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

3-11

issue

1

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(14)01282-1

journal_volume

33

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010.

    abstract::On February 17-18, 2010, the World Health Organization (WHO) convened the 6th meeting on the "Evaluation of pandemic influenza vaccines in clinical trials" to review the progress made on new A (H1N1) 2009 vaccines and prototype H5N1 vaccines and their evaluation in clinical trials. A number of vaccine types were revie...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.07.034

    authors: Girard MP,Katz J,Pervikov Y,Palkonyay L,Kieny MP

    更新日期:2010-10-04 00:00:00

  • Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study.

    abstract:BACKGROUND:Shigellae cause severe disease in endemic countries, especially in children. Several efficacy trials have been conducted with candidate vaccines against Shigellae, but the lack of protection, the safety concerns, or manufacturing challenges hindered successful market approval. Conjugated vaccines have been s...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2015.06.102

    authors: Hatz CF,Bally B,Rohrer S,Steffen R,Kramme S,Siegrist CA,Wacker M,Alaimo C,Fonck VG

    更新日期:2015-08-26 00:00:00

  • Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.

    abstract:BACKGROUND:Adjuvants like AS01B increase the immunogenicity of vaccines and generally cause increased transient reactogenicity compared with Alum. A phase II randomized trial was conducted to characterize the response to AS01B and Alum adjuvanted vaccines. A post-hoc analysis was performed to examine the associations b...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2019.02.015

    authors: Burny W,Marchant A,Hervé C,Callegaro A,Caubet M,Fissette L,Gheyle L,Legrand C,Ndour C,Tavares Da Silva F,van der Most R,Willems F,Didierlaurent AM,Yarzabal J,ECR-008 study group.

    更新日期:2019-03-28 00:00:00

  • Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.

    abstract:BACKGROUND:We have developed a new oral vaccine against enterotoxigenic Escherichia coli (ETEC), which is the most common cause of bacterial diarrhea in children in developing countries and in travelers. METHODS:The vaccine was tested for safety and immunogenicity alone and together with double-mutant heat-labile toxi...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2014.10.069

    authors: Lundgren A,Bourgeois L,Carlin N,Clements J,Gustafsson B,Hartford M,Holmgren J,Petzold M,Walker R,Svennerholm AM

    更新日期:2014-12-12 00:00:00

  • Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.

    abstract::Development of meningococcal serogroups A, C, W-135 and Y conjugate vaccines could expand coverage against devastating meningococcal diseases. The immunogenicity of one dose of each one of five MenACWY-TT formulations versus a licensed ACWY polysaccharide vaccine was evaluated in 175 healthy subjects of 15-25 years. S...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2008.08.075

    authors: Ostergaard L,Lebacq E,Poolman J,Maechler G,Boutriau D

    更新日期:2009-01-01 00:00:00

  • Improved immunogenicity of a core-coated tetanus toxoid delivery system.

    abstract::A new microparticulate delivery system composed of a stabilizing gelatin/poloxamer microcore surrounded by a PLGA coat was designed to improve the stability of tetanus toxoid (TT) encapsulated in PLGA microspheres. Microcores were prepared by a spray-congealing technique and encapsulated within PLGA using an oil-in-oi...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(99)00313-8

    authors: Tobío M,Schwendeman SP,Guo Y,McIver J,Langer R,Alonso MJ

    更新日期:1999-11-12 00:00:00

  • Memory inflation following adenoviral vaccination depends on IL-21.

    abstract::Cytomegalovirus (CMV) and non-replicating adenoviral vectors can induce expanded, sustained effector-memory CD8+ T-cell responses, termed "memory inflation". During murine CMV (MCMV) infection, CD4+ Tcells maintain inflationary virus-specific CD8+ T-cell responses via IL-2 but not IL-21. Adenovirus vector vaccination ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.09.061

    authors: Gordon CL,Hutchings CL,Highton AJ,Colston JM,Provine NM,Klenerman P

    更新日期:2018-11-12 00:00:00

  • Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants.

    abstract:BACKGROUND:Vaccinating pregnant women may prevent invasive Group B Streptococcus (GBS) disease in their young infants. In a low-middle income setting, we sought to determine an association between natural maternal antibody responses and the development of invasive GBS disease. METHODS:We undertook a matched case-contr...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.10.019

    authors: Dangor Z,Kwatra G,Izu A,Adrian P,Cutland CL,Velaphi S,Ballot D,Reubenson G,Zell ER,Lala SG,Madhi SA

    更新日期:2015-11-27 00:00:00

  • Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.

    abstract::In clinical trials recombinant-modified vaccinia virus Ankara expressing the Mycobacterium tuberculosis antigen 85A (MVA85A) induces approximately 10 times more effector T cells than any other recombinant MVA vaccine. We have found that in BCG primed subjects MVA85A vaccination reduces transforming growth factor beta ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.07.040

    authors: Fletcher HA,Pathan AA,Berthoud TK,Dunachie SJ,Whelan KT,Alder NC,Sander CR,Hill AV,McShane H

    更新日期:2008-09-26 00:00:00

  • Pulcherrimasaponin, from the leaves of Calliandra pulcherrima, as adjuvant for immunization in the murine model of visceral leishmaniasis.

    abstract::A novel triterpenoidal saponin, called pulcherrimasaponin (CP05), isolated from the leaves of Calliandra pulcherrima Benth. shows remarkable similarities to the previously described potent adjuvant, QS21 saponin (Quillaja saponaria Molina). On the basis of chemical and physicochemical evidence, its structure was estab...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.08.022

    authors: Silva BP,Soares JB,Souza EP,Palatnik M,Sousa CB,Parente JP

    更新日期:2005-01-11 00:00:00

  • Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.

    abstract::It has been known that influenza A virus infection induces a cross-protective immunity against infection by viruses with different subtypes of viral envelope proteins, hemagglutinin (HA) and neuraminidase (NA). This heterosubtypic immunity is generally mediated by cytotoxic T lymphocytes (CTL) reactive to specific epi...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(03)00234-2

    authors: Takada A,Matsushita S,Ninomiya A,Kawaoka Y,Kida H

    更新日期:2003-07-04 00:00:00

  • Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules.

    abstract::Targeted delivery of vaccine candidates to the gastrointestinal (GI) tract holds potential for mucosal immunization, particularly against mucosal pathogens like the human immunodeficiency virus (HIV). Among the different strategies for achieving targeted release in the GI tract, namely the small intestine, pH sensitiv...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.10.030

    authors: Mercier GT,Nehete PN,Passeri MF,Nehete BN,Weaver EA,Templeton NS,Schluns K,Buchl SS,Sastry KJ,Barry MA

    更新日期:2007-12-17 00:00:00

  • Protection against influenza virus infection by nasal vaccination in advance of sublethal irradiation.

    abstract::The effect of sublethal gamma-ray irradiation on the protection conferred by a nasal influenza vaccine was investigated in BALB/c mice. A radiation dose of 7 Gy was selected as the sublethal dose as this caused exacerbation of the influenza but was not lethal in the mouse model. Mice were irradiated 7 days before, on ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(99)00553-8

    authors: Hasegawa H,Kadowaki S,Takahashi H,Iwasaki T,Tamura S,Kurata T

    更新日期:2000-05-22 00:00:00

  • Sudden infant death syndrome (SIDS): are common bacterial toxins responsible, and do they have a vaccine potential?

    abstract::Despite extensive research, no unifying concept has satisfactorily explained the cause of the sudden infant death syndrome (SIDS). The details are briefly outlined of some of the evidence supporting the hypothesis that common bacterial toxins are important in the aetiology of SIDS. These bacterial toxins act as trigge...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/0264-410x(94)90102-3

    authors: Murrell TG,Murrell WG,Lindsay JA

    更新日期:1994-03-01 00:00:00

  • Decreasing invasive pneumococcal disease in the elderly: a state-level analysis.

    abstract::Evidence has accumulated supporting the relationship between the use of 7-valent pneumococcal conjugate vaccine (PCV7) in children and a decline in invasive pneumococcal disease (IPD) in the elderly. We conducted a state-level analysis of vaccination coverage rates among children 19-35 months of age and IPD hospitaliz...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.04.055

    authors: McBean AM,Jung K,Hebert PL

    更新日期:2006-07-07 00:00:00

  • Advancing a vaccine to prevent hookworm disease and anemia.

    abstract::A human hookworm vaccine is under development and in clinical trials in Africa and the Americas. The vaccine contains the Na-APR-1 and Na-GST-1 antigens. It elicits neutralizing antibodies that interfere with establishment of the adult hookworm in the gut and the ability of the parasite to feed on blood. The vaccine t...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.03.078

    authors: Hotez PJ,Beaumier CM,Gillespie PM,Strych U,Hayward T,Bottazzi ME

    更新日期:2016-06-03 00:00:00

  • Attitudes towards influenza vaccination of multi-nationality health-care workers in Saudi Arabia.

    abstract:BACKGROUND:The compliance with influenza vaccination among health-care workers (HCWs) is known to be low. A multi-nationality survey to explore the reasons for such poor compliance has not been studied in depth. MATERIALS AND METHODS:An epidemiologic survey to evaluate the compliance rates with influenza vaccination a...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.06.108

    authors: Al-Tawfiq JA,Antony A,Abed MS

    更新日期:2009-09-04 00:00:00

  • Intussusception risk after RotaTeq vaccination: evaluation from worldwide spontaneous reporting data using a self-controlled case series approach.

    abstract::The increased risk of intussusception after vaccination with the rhesus-human reassortant rotavirus vaccine Rotashield led to its withdrawal in 2005. We assess the risk of intussusception following the pentavalent rotavirus vaccine (RV5) on the basis of worldwide reports to the manufacturer up to May 2014, using a sel...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.01.005

    authors: Escolano S,Hill C,Tubert-Bitter P

    更新日期:2015-02-18 00:00:00

  • Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination.

    abstract::Seasonal influenza epidemics are associated with high morbidity and mortality particularly in high-risk patients. Conventionally administered influenza vaccines show reduced efficacy in populations with weakened immune systems such as solid-organ transplant patients. This study assesses the safety and immunogenicity o...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.vaccine.2010.08.015

    authors: Morelon E,Pouteil Noble C,Daoud S,Cahen R,Goujon-Henry C,Weber F,Laurent PE,Kaiserlian D,Nicolas JF

    更新日期:2010-10-04 00:00:00

  • Amount of maternal rotavirus-specific antibodies influence the outcome of rotavirus vaccination of newborn mice with virus-like particles.

    abstract::In presence of low or high levels of rotavirus-specific maternal antibodies, the ability of newborn mice to respond to immunization with rotavirus RF 8*-2/6/7 VLPs, was evaluated. After parenteral vaccination, 100% of offspring born to low-antibody-titer dams developed rotavirus-specific IgG antibodies (n=7). In contr...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.11.089

    authors: Johansson E,Istrate C,Charpilienne A,Cohen J,Hinkula J,Poncet D,Svensson L,Johansen K

    更新日期:2008-02-06 00:00:00

  • Enhancement of intranasal vaccination in mice with deglycosylated chain A ricin by LTR72, a novel mucosal adjuvant.

    abstract::Intranasal (i.n.) vaccination with two suboptimal doses of 8 microg of deglycosylated chain A ricin (DGCA) stimulated low anti-ricin ELISA IgG and neutralizing antibody responses and the vaccine was only marginally protective against a lethal ricin toxin aerosol challenge. However, in the presence of 4, 2, or 1 microg...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.12.034

    authors: Kende M,Del Giudice G,Rivera N,Hewetson J

    更新日期:2006-03-15 00:00:00

  • Vaccination against the 2009 pandemic influenza A (H1N1) among healthcare workers in the major teaching hospital of Sicily (Italy).

    abstract::The aim of the study was to investigate factors involved in vaccination acceptance among healthcare workers (HCWs) and adverse reactions rates associated with pandemic influenza vaccination. The study was carried out in the major teaching hospital of Sicily from November 2009 to February 2010 on 2267 HCWs. A total of ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.12.041

    authors: Amodio E,Anastasi G,Marsala MG,Torregrossa MV,Romano N,Firenze A

    更新日期:2011-02-04 00:00:00

  • Impact of the introduction of rotavirus vaccine on the timeliness of other scheduled vaccines: the Australian experience.

    abstract::Strict age limits for receipt of rotavirus vaccines and simultaneous use of vaccines requiring two (Rotarix(®)) and three (RotaTeq(®)) doses in Australia may impact on coverage and timeliness of other vaccines in the infant schedule. Using data from the Australian Childhood Immunisation Register (ACIR), coverage and t...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.02.007

    authors: Hull BP,Menzies R,Macartney K,McIntyre PB

    更新日期:2013-04-08 00:00:00

  • Generation of recombinant pandemic H1N1 influenza virus with the HA cleavable by bromelain and identification of the residues influencing HA bromelain cleavage.

    abstract::The proteolytic enzyme bromelain has been traditionally used to cleave the hemagglutinin (HA) protein at the C-terminus of the HA2 region to release the HA proteins from influenza virions. The bromelain cleaved HA (BHA) has been routinely used as an antigen to generate antiserum that is essential for influenza vaccine...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.11.101

    authors: Wang W,Suguitan AL Jr,Zengel J,Chen Z,Jin H

    更新日期:2012-01-20 00:00:00

  • Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches.

    abstract::Influenza viruses exhibit a fascinating level of antigenic heterogeneity that facilitates re-infection in the human population. The human antibody repertoire also manifests endless capability for variation in the genes that specify the portion of antibody molecules interacting with epitopes. A recent explosion of tech...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.10.124

    authors: Crowe JE Jr

    更新日期:2009-12-30 00:00:00

  • Immune response and prophylactic efficacy of smegmosomes in a hamster model of leptospirosis.

    abstract::Leptospirosis is an important zoonotic disease worldwide. Subunit vaccines are an attractive intervention strategy against this disease, but potent, non-toxic adjuvants are necessary components to any effective vaccine. Among various adjuvant candidates, liposomes have garnered recent attention for their capacity as c...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.08.029

    authors: Faisal SM,Yan W,McDonough SP,Mohammed HO,Divers TJ,Chang YF

    更新日期:2009-10-19 00:00:00

  • Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.

    abstract:BACKGROUND:Influenza A/H7N9 viruses are undergoing antigenic drift since their emergence in 2013, and vaccination strategies are needed for pandemic preparedness. Two doses of adjuvanted monovalent inactivated influenza A/H7N9 vaccine (IIV1 A/H7N9) are needed for optimal serological responses. However, administering 2 ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.03.071

    authors: El Sahly HM,Atmar RL,Patel SM,Bellamy A,Liu L,Hong W,Zhu H,Guan Y,Keitel WA,DMID 13-0033 Vaccine Study Group.

    更新日期:2019-05-01 00:00:00

  • Effect of hepatitis A vaccination schedules on immune response.

    abstract::An inactivated hepatitis A vaccine was given to 104 seronegative volunteers aged between 19 and 60 years according to two schedules: 0, 1 and 2 months or 0, 1 and 6 months. The vaccine was well tolerated and 97 and 100% of vaccinees developed a serum antibody response following a single and two doses of vaccine respec...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0264-410x(92)90563-y

    authors: Tilzey AJ,Palmer SJ,Barrow S,Perry KR,Tyrell H,Safary A,Banatvala JE

    更新日期:1992-01-01 00:00:00

  • Systems vaccinology: Enabling rational vaccine design with systems biological approaches.

    abstract::Vaccines have drastically reduced the mortality and morbidity of many diseases. However, vaccines have historically been developed empirically, and recent development of vaccines against current pandemics such as HIV and malaria has been met with difficulty. The advent of high-throughput technologies, coupled with sys...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2015.03.072

    authors: Hagan T,Nakaya HI,Subramaniam S,Pulendran B

    更新日期:2015-09-29 00:00:00

  • Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine.

    abstract::Crimean-Congo hemorrhagic fever virus (CCHFV) poses a great threat to public health due to its high mortality and transmission rate and wide geographical distribution. There is currently no specific antiviral therapy for CCHF. This study provides the first in-depth analysis of the cellular and humoral immune response ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.08.003

    authors: Mousavi-Jazi M,Karlberg H,Papa A,Christova I,Mirazimi A

    更新日期:2012-09-28 00:00:00